Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Xu, Tinga; b; 1 | Zou, Qinga; 1 | Wu, Jinga; 1 | Yu, Bina | Xu, Zichenga | Cai, Hongzhoua | Zhang, Weib; *
Affiliations: [a] Department of Urologic Surgery, The affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University, Nanjing, Jiangsu, China | [b] Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Correspondence: [*] Corresponding author: Wei Zhang, Department of Urology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 300 Guangzhou road, Nanjing 210029, Jiangsu, China. E-mail: caihong12006@gmail.com.
Note: [1] These authors contributed equally to this work.
Abstract: Objective:To examine the expression of heterogeneous nuclear ribonucleoprotein U-like 1 (hnRPUL1) and poly (ADP-ribose) polymerase 1 (PARP-1) in renal cell carcinoma (RCC) tissues and the connection between the expressions and prognosis of RCC. Material and Methods:Total RNAs were extracted from 36 pairs of RCC and their adjacent non-tumor tissues and real-time qRT-PCR was performed. Results:The expression of hnRPUL1 was remarkably downregulation in RCC tissues (14/36, 38.9%), compared with matched adjacent non-tumor tissues. And the expression of PARP1 was also remarkably downregulation in RCC tissues (12/36, 30.0%). In the stratification of clinical stage, downregulation in hnRPUL1 and PARP1 were both connected with the advanced clinical stage (P=0.013 and P=0.009). In addition, significantly increased risk of developing with a moderately and poorly differentiated tumor nuclear grade was found in the downregulation of hnRPUL1 patients (P=0.027). Conclusions:Despite the limitations, hnRPUL1 and PARP1 were downregulated in renal cell carcinoma and connected with the prognosis.
Keywords: Heterogeneous nuclear ribonucleoprotein U-like 1, Poly (ADP-ribose) polymerase 1, renal cell carcinoma
DOI: 10.3233/CBM-140390
Journal: Cancer Biomarkers, vol. 13, no. 6, pp. 411-415, 2013
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl